Polianta Ltd’s Emergent Biosolutions EBS Stock Holding History

Polianta Ltd’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-18,800	Closed	-$1.18M	–	76
2021 Q2	$1.18M	Buy	+18,800	New	+$1.21M	0.61%	43

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Polianta Ltd's EBS Position: Q3 2021 in Review

Polianta Ltd sold out of Emergent Biosolutions (EBS) in Q3 2021, closing a stake of 18,800 shares — an estimated $1.18M sold.

Polianta Ltd first reported a position in EBS in Q2 2021 and held it in 1 quarter. The position peaked at $1.18M in Q2 2021. 277 funds tracked by Wall St. Rank hold EBS as of Q3 2021.

Polianta Ltd reported no remaining Emergent Biosolutions position as of Q3 2021 after selling out during the quarter.
Polianta Ltd sold 18,800 Emergent Biosolutions shares in Q3 2021, an estimated $1.18M.
Polianta Ltd first reported a position in Emergent Biosolutions in Q2 2021 and held it in 1 quarter.
Polianta Ltd's Emergent Biosolutions position peaked at $1.18M in Q2 2021.
277 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2021.

Based on Polianta Ltd's 13F filing for Q3 2021, filed 19 Oct 2021.